Sarepta Therapeutics Ownership

SRPT Stock  USD 63.51  0.73  1.16%   
Sarepta Therapeutics shows a total of 98.26 Million outstanding shares. The majority of Sarepta Therapeutics outstanding shares are owned by institutional holders. These institutional investors are usually referred to as non-private investors looking to take positions in Sarepta Therapeutics to benefit from reduced commissions. Consequently, institutions are subject to a different set of regulations than regular investors in Sarepta Therapeutics. Please pay attention to any change in the institutional holdings of Sarepta Therapeutics as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company owns, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sarepta Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.
For more information on how to buy Sarepta Stock please use our How to Invest in Sarepta Therapeutics guide.

Sarepta Stock Ownership Analysis

About 89.0% of the company shares are owned by institutional investors. The book value of Sarepta Therapeutics was at this time reported as 15.77. The company had not issued any dividends in recent years. Sarepta Therapeutics had 1:6 split on the 12th of July 2012. Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts. Sarepta Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 840 people. To find out more about Sarepta Therapeutics contact Douglas Esq at 617 274 4000 or learn more at https://www.sarepta.com.

Sarepta Therapeutics Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Sarepta Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Sarepta Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Sarepta Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
 
Rothfuss Cristin over a month ago
Disposition of 296 shares by Rothfuss Cristin of Sarepta Therapeutics at 101.34 subject to Rule 16b-3
 
Bilal Arif over a month ago
Disposition of 17500 shares by Bilal Arif of Sarepta Therapeutics subject to Rule 16b-3
 
Rothfuss Cristin over two months ago
Insider Trading
 
Dallan Murray over two months ago
Disposition of 11723 shares by Dallan Murray of Sarepta Therapeutics at 128.67 subject to Rule 16b-3
 
Dallan Murray over two months ago
Disposition of 11723 shares by Dallan Murray of Sarepta Therapeutics at 128.67 subject to Rule 16b-3
 
Dallan Murray over two months ago
Disposition of 11723 shares by Dallan Murray of Sarepta Therapeutics at 128.67 subject to Rule 16b-3
 
Dallan Murray over two months ago
Disposition of 11723 shares by Dallan Murray of Sarepta Therapeutics at 128.67 subject to Rule 16b-3
 
Dallan Murray over three months ago
Disposition of 11723 shares by Dallan Murray of Sarepta Therapeutics at 128.67 subject to Rule 16b-3
 
Dallan Murray over three months ago
Disposition of 11723 shares by Dallan Murray of Sarepta Therapeutics at 128.67 subject to Rule 16b-3
 
Ian Estepan over three months ago
Disposition of 1533 shares by Ian Estepan of Sarepta Therapeutics at 12.0 subject to Rule 16b-3
 
Dallan Murray over three months ago
Disposition of 11723 shares by Dallan Murray of Sarepta Therapeutics at 128.67 subject to Rule 16b-3
 
Dallan Murray over three months ago
Disposition of 11723 shares by Dallan Murray of Sarepta Therapeutics at 128.67 subject to Rule 16b-3

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Sarepta Stock Analysis

When running Sarepta Therapeutics' price analysis, check to measure Sarepta Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sarepta Therapeutics is operating at the current time. Most of Sarepta Therapeutics' value examination focuses on studying past and present price action to predict the probability of Sarepta Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sarepta Therapeutics' price. Additionally, you may evaluate how the addition of Sarepta Therapeutics to your portfolios can decrease your overall portfolio volatility.